Onco-Innovations Ltd. (CBOE CA: ONCO) (OTCQB: ONNVF) (FSE: W1H) Builds Manufacturing, IND and Capital Foundation Ahead of Planned Clinical Translation
Disseminated on behalf of Onco-Innovations Ltd. (CBOE CA: ONCO) (OTCQB: ONNVF) (FSE: W1H) and may include paid advertising. Investors in biotechnology often look for companies with a clear path toward clinical development, where regulatory preparation, manufacturing readiness and access to capital can help reduce execution risk. Onco-Innovations Ltd. is advancing ONC010, a nanoparticle-encapsulated PNKP inhibitor designed to target DNA repair pathways involved in cancer survival and treatment resistance. The company has strengthened its clinical foundation through manufacturing milestones, IND-enabling activities, strategic partnerships and a recent funding arrangement designed to support continued advancement of its oncology pipeline. For biotechnology investors, a…